MedPath

Study of Low-level Laser Therapy in the Acute Treatment of Migraine

Phase 2
Conditions
Migraine Headache
Interventions
Device: Argus Migraine Treatment device
Registration Number
NCT02969642
Lead Sponsor
The San Francisco Clinical Research Center
Brief Summary

This study evaluates the treatment of migraine pain using low energy laser light to quench migraine signals issuing from the sphenopalatine ganglion (SPG).

Detailed Description

This is a double blinded, two arm study, comprising a sham laser and a treatment laser. The sham laser emits approximately 1/1000 the energy of the treatment laser.

It is presumed that pain relief from the treatment laser is achieved by exhausting the release of neurotransmitters from the SPG following laser stimulation. Subjects will be treated and subsequently queried at time intervals for their self-assessment of pain score (VAS). The time intervals include queries at 5 minutes through 2 hours post treatment. Subjects will be further contacted 24 hours and one month post treatment. Adverse events will be monitored and recorded.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria
  • headache on greater than 25 days/month on average for preceding 3 months;
  • headache on greater than 25 days in present month;
  • headache attributed to: head or neck trauma, cluster headache, specific migraine variants such as basilar artery, ophthalmoplegic, hemiplegic, etc;
  • women of child bearing age not using acceptable method of contraception;
  • pregnant or nursing women;
  • history of malignancy of any organ
  • uncontrolled: hypertension, severe psychiatric disorders, or known use of narcotics, analgesic or alcohol abuse;
  • light sensitivity;
  • retinal disease;
  • intranasal pathology.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ShamArgus Migraine Treatment deviceSham low energy laser using approximately 1/1000 th energy of treatment laser.
TreatmentArgus Migraine Treatment deviceTreatment laser.
Primary Outcome Measures
NameTimeMethod
Differences between treatment groups in pain free rates at 2 hours post treatment.2 hours post treatment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

San Francisco Clinical Research Center

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath